Pieris Pharmaceuticals Inc (FRA:PI60)

€ 10.064 0 (0%) Market Cap: 17.14 Mil Enterprise Value: -8.03 Mil PE Ratio: 0 PB Ratio: 1.10 GF Score: 44/100

Pieris Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Pieris Pharmaceuticals Inc Earnings Call Transcript
May 10, 2023

€60.88 (+0.26%)

Earnings
Q4 2022 Pieris Pharmaceuticals Inc Earnings Call Transcript
Mar 29, 2023

€107.81 (+13.84%)

Earnings
Q3 2022 Pieris Pharmaceuticals Inc Earnings Call Transcript
Nov 02, 2022

€84.64 (-4.34%)

Earnings
Q2 2022 Pieris Pharmaceuticals Inc Earnings Call Transcript
Aug 04, 2022

€129.39 (-7.06%)

Earnings
Q1 2022 Pieris Pharmaceuticals Inc Earnings Call Transcript
May 11, 2022

€175.28 (+8.92%)

Earnings
Q4 2021 Pieris Pharmaceuticals Inc Earnings Call Transcript
Mar 01, 2022

€217.6 (+1.72%)

Earnings
Q3 2021 Pieris Pharmaceuticals Inc Earnings Call Transcript
Nov 02, 2021

€321.6 (+2.50%)

Earnings
Pieris Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 30, 2021
Q2 2021 Pieris Pharmaceuticals Inc Earnings Call Transcript
Aug 04, 2021

€244.16 (+4.23%)

Earnings
Q1 2021 Pieris Pharmaceuticals Inc Earnings Call Transcript
May 17, 2021

€120.64 (-1.89%)

Earnings
Q4 2020 Pieris Pharmaceuticals Inc Earnings Call Transcript
Mar 30, 2021

€165.44 (-4.48%)

Earnings
Q3 2020 Pieris Pharmaceuticals Inc Earnings Call Transcript
Nov 04, 2020

€167.76 (-1.46%)

Earnings
Pieris Pharmaceuticals, Inc. - Special Call Transcript
Sep 21, 2020
Pieris Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference Sponsored by H C Wainwright (Virtual) Transcript
Sep 16, 2020
Pieris Pharmaceuticals Inc at Robert W Baird Global Healthcare Conference (Virtual) Transcript
Sep 09, 2020
Q2 2020 Pieris Pharmaceuticals Inc Earnings Call Transcript
Aug 10, 2020

€179.68 (-1.45%)

Earnings
Pieris Pharmaceuticals Inc Annual Shareholders Meeting Transcript
Jun 23, 2020
Q1 2020 Pieris Pharmaceuticals Inc Earnings Call Transcript
May 11, 2020

€208.08 (+10.35%)

Earnings
Full Year 2019 Pieris Pharmaceuticals Inc Earnings Call Transcript
Mar 12, 2020

€154.24 (-5.95%)

Earnings
Pieris Pharmaceuticals, Inc. - Special Call Transcript
Nov 19, 2019
Q3 2019 Pieris Pharmaceuticals Inc Earnings Call Transcript
Nov 11, 2019

€280.08 (+5.14%)

Earnings
Q2 2019 Pieris Pharmaceuticals Inc Earnings Call Transcript
Aug 01, 2019

€393.64 (-4.92%)

Earnings
Q1 2019 Pieris Pharmaceuticals Inc Earnings Call Transcript
May 10, 2019

€222.92 (+2.46%)

Earnings
Full Year 2018 Pieris Pharmaceuticals Inc Earnings Call Transcript
Mar 12, 2019

€216.8 (+5.86%)

Earnings

Q2 2021 Pieris Pharmaceuticals Inc Earnings Call Transcript

Aug 04, 2021 / 12:00PM GMT

Release Date Price: €244.16 (+4.23%)

Transcript 10-Q8-K

Operator

Greetings, and welcome to the Pieris Pharmaceuticals' Second Quarter Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Tom Bures, Vice President, Finance. Thank you. You may begin.

Thomas Bures

Pieris Pharmaceuticals, Inc. - VP of Finance

Good morning, everyone, and thank you for joining us for our second quarter 2021 conference call and corporate update. On the call today, we have Steve Yoder, our President and CEO, who will provide a corporate overview and outlook on our pipeline; Hitto Kaufmann, our Chief Scientific Officer; and Shane Olwill, our Chief Development Officer, who will be available for Q&A. We also have on the line Tim Demuth, our Chief Medical Officer, who joined us just this week who will introduce himself later in the call. You can access the press release released this morning on the Investor Relations page of our website at www.pieris.com.

Before we begin, I'd

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.